Fidelity® Select Pharmaceuticals Port
(FPHAX)
US Markets Closed
AdChoices
21.62
+0.23
+1.08%
:

Previous Close

21.39

Net Assets

1.58B

Yield

0.86%

Front load

None

Expenses

0.81%

Category

Health

Morningstar Risk

Average

Morningstar Rating ★★★★
AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Top Rated Funds
  • Fund vs. Category
Quarterly Returns
  • Annual

  • FPHAX

  • Category

    • 2013

    • 41.36%

    • -

    • 2012

    • 14.25%

    • -

    • 2011

    • 13.70%

    • -

    • 2010

    • 16.36%

    • -

    • 2013

    • 2012

    • 2011

      • Q1

      • 12.70%

      • 6.63%

      • 6.65%

      • Q2

      • 3.95%

      • 2.31%

      • 7.39%

      • Q3

      • 7.44%

      • 6.11%

      • -10.69%

      • Q4

      • 12.31%

      • -1.30%

      • 11.15%

      Composition
      Sector Weightings
      Equity Investment Style
      The two dimensions of the Fund Style box measure the average size of companies that have been in the FUND, from the top to bottom, and the average valuation characteristics of the FUND's past stock holdings, from left to right.
      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Actavis PLC

        • 8.79

        • 594,907

        • -6,600

        • AbbVie Inc

        • 7.28

        • 2,024,190

        • 17,500

        • AstraZeneca PLC ADR

        • 5.34

        • 1,079,100

        • -50,400

        • Novartis AG ADR

        • 5.12

        • 875,298

        • -36,800

        • Bristol-Myers Squibb Company

        • 5.00

        • 1,517,210

        • 17,400

        • Johnson & Johnson

        • 4.90

        • 725,700

        • -67,300

        • Shire PLC ADR

        • 4.32

        • 271,500

        • -9,300

        • Merck & Co Inc

        • 4.31

        • 1,102,336

        • -80,900

        • Perrigo Co PLC

        • 3.92

        • 405,252

        • -17,200

        • Valeant Pharmaceuticals International Inc

        • 3.47

        • 455,127

        • -14,000

        • Name

        • Rating

        • YTD Return %

          • Prudential Jennison Health Sciences Z

          • ★★★★★
          • 18.82

          • VALIC Company I Health Sciences

          • ★★★★★
          • 19.62

          • Prudential Jennison Health Sciences A LW

          • ★★★★★
          • 18.54

          • T. Rowe Price Health Sciences

          • ★★★★★
          • 19.88

          • BlackRock Health Sciences Opps Inv A LW

          • ★★★★
          • 18.15

          • BlackRock Health Sciences Opps Inv C

          • ★★★★
          • 17.47

          • Fidelity Advisor® Biotechnology A

          • ★★★★
          • 19.77

          • Janus Global Life Sciences D

          • ★★★★
          • 20.52

          • Prudential Jennison Health Sciences B

          • ★★★★
          • 17.87

          • Janus Global Life Sciences A

          • ★★★★
          • 20.34

          • Name

          • FPHAX

          • Category

            • Expense Ratio

            • 0.81%

            • 1.45%

            • Net Assets

            • 1.58B

            • 711.24M

            • Dividend Yield

            • 1.51%

            • 0.61

            • Price/Book

            • 3.52

            • 4.82

            • Price/Sales

            • 3.54

            • 3.25

            • Price/Cash Flow

            • 16.34

            • 19.29

            Profile

            Name of Issuer

            Fidelity Investments

            Fund Style

            Open

            Fund Manager

            Asher Anolic

            Investment Style

            Large Growth

            The investment seeks capital appreciation. The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.

            Purchase Information

            Initial Purchase 2,500
            Initial Purchase: IRA 500
            Initial Purchase: AIP 2,500
            Front load None
            Back Load None

            Inception

            6/18/2001